Virbac SA (VIRP.PA) is set to report earnings on April 27, 2026. The European veterinary pharmaceutical company trades at €379.50 with a market cap of €3.21 billion. Recent momentum shows strength, with the stock up 4.83% and trading near 52-week highs. Investors are watching closely as the company serves companion and food-producing animals globally. Meyka AI rates VIRP.PA with a grade of B+, reflecting solid fundamentals in the healthcare sector. This earnings recap examines what the results mean for shareholders and the stock’s forward trajectory.
Stock Performance and Market Position
Virbac SA shows strong recent momentum heading into earnings. The stock trades at €379.50, up 4.83% on the day with solid volume activity. Over the past year, VIRP.PA has gained 26.99%, significantly outpacing many peers in the drug manufacturing sector.
Trading Metrics and Valuation
The company trades at a P/E ratio of 21.31x, reflecting moderate valuation relative to growth prospects. With 8.38 million shares outstanding, the market values Virbac at €3.21 billion. The 50-day moving average sits at €353.89, while the 200-day average is €345.84, indicating an uptrend. Volume remains healthy at 2,139 shares traded, though below the 5,294 average.
Technical Strength
Technical indicators show mixed signals. The RSI at 71.39 suggests overbought conditions, while the MACD histogram of 2.62 indicates positive momentum. The stock trades within Bollinger Bands, with the upper band at €371.75 and lower at €340.90. This positioning suggests room for consolidation before the next major move.
Financial Health and Key Metrics
Virbac demonstrates solid financial fundamentals with strong profitability metrics. The company generates €174.18 in revenue per share and €17.94 in net income per share on a trailing twelve-month basis. These metrics reflect consistent operational performance across its global veterinary product portfolio.
Profitability and Margins
The company maintains a net profit margin of 10.30%, showing efficient cost management. Operating margin stands at 14.89%, while gross margin is 35.36%. Return on equity reaches 13.78%, indicating effective capital deployment. Free cash flow per share of €12.63 provides flexibility for dividends and reinvestment.
Balance Sheet Strength
Virbac carries a debt-to-equity ratio of 0.26, reflecting conservative leverage. The current ratio of 1.53 demonstrates adequate liquidity for operations. Interest coverage of 21.61x shows the company easily services debt obligations. Working capital of €275.6 million supports ongoing business needs and strategic initiatives.
Dividend and Shareholder Returns
The company pays €1.45 per share in annual dividends, yielding 0.38%. The payout ratio of 8.05% leaves room for earnings reinvestment. This conservative approach balances shareholder returns with growth investment.
Growth Trajectory and Forward Outlook
Virbac shows measured growth across key metrics. Revenue grew 4.82% year-over-year, while net income increased 3.85%. Earnings per share expanded 3.69%, reflecting both operational growth and modest share count reduction. These results demonstrate steady progress in a competitive healthcare market.
Historical Growth Performance
Over five years, revenue per share grew 57.64%, while net income per share expanded just 11.52%. This divergence reflects margin compression from competitive pressures and input cost inflation. However, three-year net income growth of 24.55% shows recent improvement in profitability trends.
Forward Guidance and Forecasts
Analyst forecasts suggest modest appreciation ahead. The yearly price target stands at €351.21, slightly below current levels. However, five-year forecasts reach €376.05, implying 1.0% annualized returns. These projections reflect expectations for steady but unspectacular growth in the veterinary pharmaceutical sector.
Sector Dynamics
The drug manufacturing sector faces ongoing pricing pressures and regulatory scrutiny. Virbac’s diversified product portfolio across vaccines, parasiticides, and dermatology products provides some insulation. Geographic diversification across Europe, Americas, and Asia-Pacific reduces regional concentration risk.
Investment Perspective and Meyka AI Rating
Meyka AI rates VIRP.PA with a B+ grade, reflecting balanced risk-reward characteristics. The company scores well on return on assets (5/5) and return on equity (4/5), indicating efficient asset utilization. However, the debt-to-equity score of 1/5 suggests room for improved capital structure optimization.
Valuation Assessment
At 21.31x P/E, Virbac trades at a reasonable premium to the broader market. The price-to-sales ratio of 2.19x reflects moderate valuation relative to revenue generation. The PEG ratio of 1.61 suggests the stock is fairly valued relative to growth expectations, neither cheap nor expensive.
Risk Factors
Key risks include regulatory changes affecting veterinary pharmaceuticals, competitive pricing pressure, and currency fluctuations across international markets. The company’s 63,650 employees across global operations create execution complexity. Supply chain disruptions could impact product availability and margins.
Buy Recommendation Context
The A- company rating with a “Buy” recommendation reflects confidence in fundamentals. Strong ROA and ROE scores support the positive view. However, investors should monitor debt levels and margin trends closely for any deterioration.
Final Thoughts
Virbac SA demonstrates solid operational performance with steady growth and strong financial health. The company’s B+ Meyka AI grade reflects balanced fundamentals, with particular strength in profitability metrics and return on equity. Trading at €379.50 with a market cap of €3.21 billion, VIRP.PA offers exposure to the growing global veterinary pharmaceutical market. While growth rates remain modest at 3-5% annually, the company’s diversified product portfolio, conservative balance sheet, and consistent dividend support a stable investment profile. Investors should monitor upcoming earnings for any changes in margin trends or guidance that could signal shifts in competitive dynamics or operational efficiency.
FAQs
What is Virbac SA’s current stock price and market valuation?
VIRP.PA trades at €379.50 with a market cap of €3.21 billion. The stock is up 4.83% recently and has gained 26.99% over the past year. The P/E ratio stands at 21.31x, reflecting moderate valuation in the healthcare sector.
How does Virbac’s profitability compare to peers?
Virbac maintains a 10.30% net profit margin and 13.78% return on equity. Operating margin of 14.89% demonstrates efficient operations. These metrics reflect solid profitability relative to drug manufacturers, though growth rates remain modest at 3-5% annually.
What is Meyka AI’s rating for VIRP.PA?
Meyka AI rates VIRP.PA with a B+ grade and a “Buy” recommendation. The company scores 5/5 on return on assets and 4/5 on return on equity, indicating efficient capital deployment and strong profitability metrics.
Is Virbac’s dividend sustainable?
Yes. Virbac pays €1.45 per share annually with a 0.38% yield. The 8.05% payout ratio is conservative, leaving substantial room for reinvestment. Free cash flow of €12.63 per share easily covers dividend obligations.
What are the main risks for Virbac investors?
Key risks include regulatory changes in veterinary pharmaceuticals, competitive pricing pressure, currency fluctuations, and supply chain disruptions. The company’s global operations create execution complexity. Margin compression from input costs remains a concern.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)